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LETTER TO THE EDITOR
Kounis syndrome: A new etiologic factor  
of myocardial infarction with non-obstructive  
coronary arteries — Author response
Javier Lopez Pais1, 2, Barbara Izquierdo Coronel1, Maria Jesus Espinosa Pascual1,  
David Galán Gil1, Blanca Alcón Durán1, Joaquin Jesus Alonso Martin1
1Department of Cardiology, University Hospital of Getafe, Spain 
2Department of Cardiology, University Hospital Complex of Santiago de Compostela, Spain
It is an honour that Kounis et al. [1] decided to 
write a letter to complete this report published in 
“Cardiology Journal” a few months ago [2]. It was 
also a pleasure to learn more about this interesting 
entity directly from Dr. Kounis.
Given the latest research on myocardial in-
farction with non-obstructive coronary arteries 
(MINOCA) patients and following the recommen-
dations of the European Society of Cardiology 
(ESC), this Working Group position paperon the 
present topic [3], it is extremely important to 
perform an etiological diagnosis that identifies the 
underlying cause in order to optimize treatment.
Within these cases, the scope of endothelial 
dysfunction and microcirculation ischemia are the 
subject of many current studies.
Immunomodulation and cardiovascular disease 
is a fascinating issue which is taken as more of 
a protagonist on a daily basis. Two outstanding 
studies have recently been published concerning 
this field. Kwong et al. [4] have shown the link 
between the flu and myocardial infarction, and the 
CANTOS study shows the impact of immunomodu-
latory treatment on cardiovascular risk [5]; as did 
the present group in an abstract presented at the 
ESC Congress [6].
Anaphylaxis is a stressful situation which may 
lead to different scenarios, including takotsubo 
syndrome and vasospasm, both potential underly-
ing causes of MINOCA.
Kounis syndrome may have a place in MINOCA 
etiology because of its main physiopathological 
mechanism, being that this syndrome is described 
as an concurrence of acute coronary syndrome with 
conditions associated with mast cell activation in-
cluding allergic or hypersensitivity,  anaphylactic 
or anaphylactoid insults [7, 8].
However, in these cases were an allergy in-
sult MINOCA concurs, it is hard to say whether 
the myocardial injury is caused by the release of 
inflammatory mediators itself, or if it is caused by 
other coexisting conditions.
In this MINOCA series [2], there was 1 patient 
who had a MINOCA after an allergic insult. It may 
have fulfilled criteria of Kounis syndrome type I 
(patients with normal coronary arteries in whom an 
acute allergic insult leads to coronary artery spasm 
with infarction with positive cardiac biomarkers). 
Nevertheless, it could not demonstrated that 
the presence of a vasospasm and the mechanism 
underlying the acute event of that patient was 
considered a type II myocardial infarction caused 
by tachycardia and hypertension after epinephrine.
As had been expressed, it was hard to decide 
which etiological group these patients belonged to, 
because many of the patients with anaphylactic reac-
tions receive epinephrine, which could cause angina, 
electrocardiogram abnormalities, and even troponin 
elevation itself. In addition to that, an allergic epi-
sode in itself can cause myocardial damage due to 
coronary hypoperfusion in the context of reduced 
cardiac output derived from severe systemic vaso-
dilation. In some cases, even takotsubo syndrome 
due to a stressful situation could be an explanation.
Regarding treatment and secondary preven-
tion, the most important in these patients is to 
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take the allergy trigger into account, because 
special tests need to be run. Nowadays, there is 
insufficient evidence to decide upon the indication 
of treatment with mast cell surface membrane 
protectors. Given this, the present  patient was 
referred to the Immunology Department and ESC-
-guidelines based treatment was prescribed.
It was believed that with these types of stud-
ies, more could be learned about the effects of 
proinflammatory conditions and their effect on 
myocardial cells, not only to treat cardiovascular 
diseases but also to improve their primary and 
secondary prevention.
The efforts of Dr. Kounis are much appreci-
ated in describing a concrete entity that each pro-
fessional should take into account when treating 
patients, and it is hoped  that all can continue with 
the study of allergy and inflammation as emerging 
risk factors for coronary artery disease.
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